公开(公告)号：US20050043545A1

公开(公告)日：2005-02-24

申请号：US10494114

申请日：2002-10-30

申请人： Gianpalol Bravi ,  Helene Goodland ,  David Haigh ,  Charles Hartley ,  Victoria Lovegrove ,  Pritom Shah ,  Martin Slater

发明人： Gianpalol Bravi ,  Helene Goodland ,  David Haigh ,  Charles Hartley ,  Victoria Lovegrove ,  Pritom Shah ,  Martin Slater

IPC分类号： A61K31/4196 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/428 ,  A61K31/433 ,  A61K31/4439 ,  A61P1/16 ,  A61P31/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D43/02

CPC分类号： C07D409/14 ,  C07D413/14 ,  C07D417/14

摘要： Novel anti-viral agents of Formula wherein: A represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; C represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; D represents a saturated or unsaturated optionally substituted 5-membered heterocyclic ring; E represents hydrogen or C1-6alkyl; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts and solvates thereof, processes for their preparation and methods of using them in HCV treatment are provided.

摘要翻译： 新型的式的抗病毒剂其中：A表示OR 1，NR 1 R 2或R 1，其中R 1和R 2是氢，C 1-6烷基，芳基，杂芳基 ，芳基烷基或杂芳基烷基; 或R 1和R 2与它们所连接的氮原子一起形成5或6元饱和环状基团; B表示C（O）R 3，其中R 3是C 1-6烷基，芳基，杂芳基，芳烷基或杂芳基烷基; C代表C 1-6烷基，芳基，杂芳基或杂环基; D表示饱和或不饱和的任选取代的5元杂环; E表示氢或C 1-6烷基; F表示氢，C 1-6烷基，芳基或杂芳基; 和G表示氢，C 1-6烷基，杂环基烷基，芳基烷基或杂芳基烷基; 并提供其盐和溶剂化物，其制备方法及其在HCV治疗中的使用方法。

公开(公告)号：US20050043390A1

公开(公告)日：2005-02-24

申请号：US10494127

申请日：2002-10-30

申请人： Gianpaolo Bravi ,  Rossella Guidetti ,  David Haigh ,  Charles Hartley ,  Peter Howes ,  Deborah Jackson ,  Victoria Lovegrove ,  Pritom Shah ,  Martin Slater ,  Katrina Wareing

发明人： Gianpaolo Bravi ,  Rossella Guidetti ,  David Haigh ,  Charles Hartley ,  Peter Howes ,  Deborah Jackson ,  Victoria Lovegrove ,  Pritom Shah ,  Martin Slater ,  Katrina Wareing

IPC分类号： A61K31/4439 ,  A61K31/497 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61P1/16 ,  A61P31/12 ,  A61P31/14 ,  C07D401/14 ,  C07D403/04 ,  C07D409/14 ,  C07D417/14 ,  A61K31/4025 ,  A61K31/401 ,  C07D43/02

CPC分类号： C07D401/14 ,  C07D403/04 ,  C07D409/14 ,  C07D417/14

摘要： Novel anti-viral agents of Formula wherein: A represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; C represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; D represents a saturated or unsaturated optionally substituted 6-membered heterocyclic ring; E represents hydrogen or C1-6-alkyl; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and esters thereof, processes for their preparation and methods of using them in HCV treatment are provided.

摘要翻译： 新型的式的抗病毒剂其中：A表示OR 1，NR 1 R 2或R 1，其中R 1和R 2是氢，C 1-6烷基，芳基，杂芳基 ，芳基烷基或杂芳基烷基; 或R 1和R 2与它们所连接的氮原子一起形成5或6元饱和环状基团; B表示C（O）R 3，其中R 3是C 1-6烷基，芳基，杂芳基，芳烷基或杂芳基烷基; C代表C 1-6烷基，芳基，杂芳基或杂环基; D表示饱和或不饱和的任选取代的6元杂环; E表示氢或C 1-6 - 烷基; F表示氢，C 1-6烷基，芳基或杂芳基; 和G表示氢，C 1-6烷基，杂环基烷基，芳基烷基或杂芳基烷基; 提供其盐，溶剂合物和酯，其制备方法及其用于HCV治疗的方法。

公开(公告)号：US20050009873A1

公开(公告)日：2005-01-13

申请号：US10494121

申请日：2002-10-30

申请人： Gianpaolo Bravi ,  Peter Howes ,  Victoria Lovegrove ,  Pritom Shah ,  Martin Slater

发明人： Gianpaolo Bravi ,  Peter Howes ,  Victoria Lovegrove ,  Pritom Shah ,  Martin Slater

IPC分类号： A61K31/4025 ,  A61P31/12 ,  A61P31/14 ,  A61P31/20 ,  C07D417/04 ,  C07 ,  A61K31/401 ,  A61K31/454

CPC分类号： C07D417/04

摘要： Novel anti-viral agents of Formula (I) wherein: A represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; D represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; E represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts and solvates thereof, processes for their preparation and methods of using them in HCV treatment are provided.

摘要翻译： 式（I）的新型抗病毒剂，其中：A表示OR 1，NR 1 R 2或R 1，其中R 1和R 2为氢，C 1-6烷基， 芳基，杂芳基，芳基烷基或杂芳基烷基; 或R 1和R 2与它们所连接的氮原子一起形成5或6元饱和环状基团; B表示C（O）R 3，其中R 3是C 1-6烷基，芳基，杂芳基，芳烷基或杂芳基烷基; D表示C 1-6烷基，芳基，杂芳基或杂环基; E表示OR 1，NR 1 R 2或R 1，其中R 1和R 2是氢，C 1-6烷基，芳基，杂芳基，芳烷基或杂芳基烷基; 或R 1和R 2与它们所连接的氮原子一起形成5或6元饱和环状基团; F表示氢，C 1-6烷基，芳基或杂芳基; 和G表示氢，C 1-6烷基，杂环基烷基，芳基烷基或杂芳基烷基; 并提供其盐和溶剂化物，其制备方法及其在HCV治疗中的使用方法。